Key Takeaways
- Bethany Sensenig has been appointed to Alpha Cognition’s Board of Directors, effective April 15, 2026.
- Ms. Sensenig brings extensive experience in finance and corporate strategy from her roles in notable biopharmaceutical companies.
- Len Mertz, a founding board member, will not seek re-election, marking the end of a significant tenure with the company.
Leadership Changes at Alpha Cognition
Alpha Cognition Inc. has appointed Bethany Sensenig to its Board of Directors, effective April 15, 2026, bolstering its leadership team as it prepares to launch its drug, ZUNVEYL. With a robust background in finance and operations, Sensenig has held key positions in several biopharmaceutical companies, most recently as Chief Financial Officer at Radius Health, Inc.
Michael McFadden, the CEO of Alpha Cognition, expressed enthusiasm for Sensenig’s appointment, noting that her diverse industry experience will be vital for the company’s commercial launch of ZUNVEYL and the advancement of its clinical programs.
Sensenig’s career includes pivotal roles at 9 Meters Biopharma and Minovia Therapeutics, and she has also contributed over 13 years to Biogen Inc. There, she managed finances for a portfolio producing over $1 billion in annual revenue across more than 30 countries. Currently, she also serves on the boards of Supernus Pharmaceuticals and KalVista Pharmaceuticals.
In other board news, Len Mertz has announced he will not seek re-election. As a founding member, Mertz has played an instrumental role in guiding Alpha Cognition through its initial public offering and advancing its product pipeline. The management team expresses gratitude for his contributions and wishes him well in his future endeavors.
Alpha Cognition is focused on developing innovative therapies for neurodegenerative disorders, including Alzheimer’s disease and mild traumatic brain injury (mTBI). Its leading drug, ZUNVEYL, is an acetylcholinesterase inhibitor designed to treat Alzheimer’s with fewer gastrointestinal side effects compared to existing treatments. The drug’s unique formulation binds to neuronal nicotinic receptors, thereby enhancing cognition.
The biopharmaceutical firm is also advancing other products, including ALPHA-1062, targeted specifically for moderate to severe Alzheimer’s dementia and mTBI.
The company includes a forward-looking statement warning investors about potential risks associated with regulatory approvals, capital requirements, and market adoption of its products. This serves as a reminder of the inherent uncertainties in the biopharmaceutical industry. Continued updates and detailed disclosures about these risks are provided in the company’s filings with both Canadian and U.S. securities regulatory authorities.
The content above is a summary. For more details, see the source article.